Featured Research

from universities, journals, and other organizations

Movement disorder symptoms are lessened by an antibiotic: Treating worms with ampicillin helps restore normal movement

Date:
March 11, 2010
Source:
Disease Models and Mechanisms
Summary:
Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to scientists.

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

"It's our hope that this discovery serves as the impetus for a proper clinical trial to evaluate the potential of drugs like ampicillin for early-onset torsion dystonia," said Dr. Guy Caldwell, associate professor of biological sciences at The University of Alabama. Dystonia is, like Parkinson's disease, a movement disorder. Combined, this class of diseases affects millions worldwide. People with early-onset dystonia have one good copy of the gene DYT1, and one problematic copy, in their DNA. These genes contain the information to make a protein called torsinA.

"When proteins go bad, they often cause disease, but they always have a normal function in our cells," Guy Caldwell said. "We looked to find molecules -- not necessarily that reversed the mutated form of the protein -- but instead enhanced the normal activity of the protein, thereby overcoming the deficiency caused by the mutant."

The UA researchers discovered that ampicillin, a common antibiotic of the penicillin group, serves to activate torsinA, which, in its normal form, appears to protect cells from stresses, such as protein misfolding -- a problem known to impact various movement disorders.

Using a nematode animal model designed to evaluate torsinA activity, the UA lab rapidly screened through hundreds of compounds to identify those that were most effective at enhancing torsinA's normally protective function.

"From there, we collaborated with researchers at Harvard and UAB to validate our findings in human patient cells and mice," said Dr. Kim Caldwell, associate professor of biological sciences at UA.

"In human dystonia patient cells, ampicillin was efficacious and restored the patient cells back to the normal function," Kim Caldwell said. "And, the drug restored normal movement to mice that were genetic mimics of dystonia."

Collaborators in the UA-led study were Drs. Xandra O. Breakefield and her colleagues at Harvard and Yuqing Li and his colleagues at The University of Alabama at Birmingham, known as UAB. Dr. Songsong Cao, a former doctoral student in the Caldwell Lab, is the study's lead author; two UA doctoral students, Alexander J. Burdette and Pan Chen; and one former UA student, Amber Clark Buckley, are among the co-authors.

Furthermore, the research shows ampicillin enhances the capacity of torsinA to protect, within animal models, the neurons which produce dopamine from dying. The death of these neurons in human brains leads to the hallmark symptoms of Parkinson's disease.

In a statement accompanying the paper, the researchers caution against the long-term use of an antibiotic in disease treatment.

"We have taken ampicillin and used that as a base structure to find things that work like ampicillin but which aren't ampicillin," Guy Caldwell said. "Finding molecules that are not antibiotic and still have the capacity to activate torsinA has been an ongoing effort of our lab, and we have some exciting leads in that direction."

UA filed patents covering the use of antibiotics and other novel chemicals as activators of torsinA for treatment of dystonia and other diseases, including Parkinson's disease. The University has also entered into a collaborative research and licensing agreement with QRxPharma, a clinical stage pharmaceutical company, to identify, develop and commercially exploit new torsinA activator drugs.

The UA/QRxPharma research program is directed at re-engineering existing drug therapies for new clinical applications and identifying new drug candidates for uses including the treatment of dystonia, Parkinson's disease and other neurological disorders.

The project exemplifies, the researchers said, how disease model systems can be used to accelerate the development of gene and drug discovery and bring pharmaceuticals more quickly to the clinical trial stage.

Bringing a drug that does not already have FDA approval from the research and development stage to a patient takes an estimated 12 years and $800 million dollars, said Kim Caldwell. By evaluating the potential of molecules already pre-screened for toxicity and that have FDA approval provides a potentially quicker route to clinical trials.

"What we were hoping to do was circumvent a lot of the cost in bringing pharmaceutical help to dystonia patients," Kim Caldwell said.

The research was supported by the Bachmann-Strauss Dystonia and Parkinson Foundation, Dystonia Medical Research Foundation, the Jack Fasciana Fund for Dystonia Research and the National Institutes of Health.


Story Source:

The above story is based on materials provided by Disease Models and Mechanisms. Note: Materials may be edited for content and length.


Cite This Page:

Disease Models and Mechanisms. "Movement disorder symptoms are lessened by an antibiotic: Treating worms with ampicillin helps restore normal movement." ScienceDaily. ScienceDaily, 11 March 2010. <www.sciencedaily.com/releases/2010/03/100310162827.htm>.
Disease Models and Mechanisms. (2010, March 11). Movement disorder symptoms are lessened by an antibiotic: Treating worms with ampicillin helps restore normal movement. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2010/03/100310162827.htm
Disease Models and Mechanisms. "Movement disorder symptoms are lessened by an antibiotic: Treating worms with ampicillin helps restore normal movement." ScienceDaily. www.sciencedaily.com/releases/2010/03/100310162827.htm (accessed April 24, 2014).

Share This



More Mind & Brain News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Marijuana Use Lead To Serious Heart Problems?

Could Marijuana Use Lead To Serious Heart Problems?

Newsy (Apr. 24, 2014) A new study says marijuana use could lead to serious heart-related complications. Video provided by Newsy
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com
Do We Get Nicer With Age?

Do We Get Nicer With Age?

Newsy (Apr. 22, 2014) A recent report claims personality can change over time as we age, and usually that means becoming nicer and more emotionally stable. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins